TSS
IBO

Two Sigma Securities’s Impact BioMedical IBO Stock Holding History

Two Sigma Securities’s Portfolio IBO Stock Details IBO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-22,695
Closed -$11.5K – 2322
2025
Q4 		$11.5K Sell
22,695
-5,746
-20% -$3.04K ﹤0.01% 1273
2025
Q3 		$18.9K Buy
+28,441
New +$17.9K ﹤0.01% 1148

Other funds holding IBO

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VGA
Vanguard Global Advisers Malvern, Pennsylvania $187B AUM
MAC
Mason & Associates (California) Los Angeles, California $619M AUM 29.44% 1-Year Est. Return

Two Sigma Securities's IBO Position: Q1 2026 in Review

Two Sigma Securities sold out of Impact BioMedical (IBO) in Q1 2026, closing a stake of 22,695 shares — an estimated $11.5K sold.

Two Sigma Securities first reported a position in IBO in Q3 2025 and held it in 2 quarters. The position peaked at $18.9K in Q3 2025. 20 funds tracked by Wall St. Rank hold IBO as of Q1 2026.

  • Two Sigma Securities reported no remaining Impact BioMedical position as of Q1 2026 after selling out during the quarter.
  • Two Sigma Securities sold 22,695 Impact BioMedical shares in Q1 2026, an estimated $11.5K.
  • Two Sigma Securities first reported a position in Impact BioMedical in Q3 2025 and held it in 2 quarters.
  • Two Sigma Securities's Impact BioMedical position peaked at $18.9K in Q3 2025.
  • 20 funds tracked by Wall St. Rank held Impact BioMedical as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.